A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail
Phase 1
Active, not recruiting
- Conditions
- Hereditary angioedemaTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of deucrictibant on P-gp and BCRP substrates in healthy subjects?
How does deucrictibant compare to standard-of-care C1 esterase inhibitors in hereditary angioedema management?
Which biomarkers correlate with deucrictibant's efficacy in plasma kallikrein inhibition for HAE patients?
What are the potential drug-drug interaction risks of deucrictibant with P-gp/BCRP substrates in clinical practice?
How do plasma kallikrein inhibitors like deucrictibant and lanadelumab differ in their pharmacokinetic profiles for HAE treatment?